Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unveiling the Veil of JAK Inhibitors
Unveiling the Veil of JAK Inhibitors
4 September 2023
JAK inhibitors can inhibit JAK kinases, block the JAK-STAT signaling pathway, and have great therapeutic potential for a variety of diseases including tumors, immune & inflammation···
Read →
Analysis of Amgen’s Drug Development Pipeline | R&D Progress | Drug Target
R&D Pipeline
4 min read
Analysis of Amgen’s Drug Development Pipeline | R&D Progress | Drug Target
4 September 2023
Amgen Inc. is a biotechnology company dedicated to providing biological therapeutics to patients with serious diseases by discovering, developing, manufacturing, and delivering innovative human therapies.
Read →
The U.S. has granted IND approval to HBM9033, the initial ADC project for solid tumors by Harbour BioMed
Latest Hotspot
4 min read
The U.S. has granted IND approval to HBM9033, the initial ADC project for solid tumors by Harbour BioMed
4 September 2023
Harbour BioMed declared that the U.S. FDA has given the go-ahead for the IND application, permitting the initiation of clinical studies for its inaugural Antibody Drug Conjugate (ADC) project, HBM9033.
Read →
Decoding Bromocriptine Mesylate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
5 min read
Decoding Bromocriptine Mesylate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
4 September 2023
This article summarized the latest R&D progress of Bromocriptine Mesylate, the Mechanism of Action for Bromocriptine Mesylate, and the drug target R&D trends for Bromocriptine Mesylate.
Read →
MAO Inhibitors -the Redemption of Depression
MAO Inhibitors -the Redemption of Depression
4 September 2023
Monoamine Oxidase(MAO) is a naturally existing oxidase in the human body, located on the outer membrane of mitochondria.
Read →
Review of Alkermes Plc’s Drug Pipeline | R&D Status | Therapeutic Areas
R&D Pipeline
5 min read
Review of Alkermes Plc’s Drug Pipeline | R&D Status | Therapeutic Areas
4 September 2023
Alkermes Plc is a biopharmaceutical company focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction, and multiple sclerosis.
Read →
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
Latest Hotspot
4 min read
The FDA has given its approval to Mallinckrodt for marketing Dextroamphetamine for managing Attention Deficit/Hyperactivity Disorder (ADHD)
4 September 2023
The FDA has given Mallinckrodt the green light to market Lisdexamfetamine Dimesylate Capsules, a product intended to mitigate Attention-Deficit/Hyperactivity Disorder (ADHD).
Read →
Bifonazole: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Bifonazole: Detailed Review of its Transformative R&D Success, Mechanism of Action, and Drug Target
4 September 2023
This article summarized the latest R&D progress of Bifonazole, the Mechanism of Action for Bifonazole, and the drug target R&D trends for Bifonazole.
Read →
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
ACE inhibitor -Overview of its R&D Progress | Competitive Landscape | Key Drug
4 September 2023
ACE, or angiotensin-converting enzyme, plays a crucial role in the human body by regulating blood pressure and fluid balance.
Read →
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
Latest Hotspot
4 min read
AstraZeneca's BTK Inhibitor Acalabrutinib gets Approval for New Indications in China
3 September 2023
On September 1, 2023, the NMPA officially approved a new indication for AstraZeneca's blood cancer product, Acalabrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Read →
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
Latest Hotspot
3 min read
Mabspace Biosciences initiates global Phase III clinical trials for CLDN 18.2 monoclonal antibody TST001
3 September 2023
On September 1, 2023, Mabspace Biosciences registered an international multicenter Phase III clinical trial on the Drug Clinical Trial Registration and Information Publicity Platform.
Read →
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
Latest Hotspot
4 min read
Zai Lab's new drug Maqituxi Monoclonal Antibody Injection targeting HER2 has been approved in China
3 September 2023
Margetuximab is an Fc-optimized monoclonal antibody acting on HER2, which was introduced by Zai Lab from MacroGenics.
Read →